Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study of the Oral RET Inhibitor LOXO 292 in Pediatric Patients With Advanced RET-Altered Solid or Primary Central Nervous System Tumors

NCT03899792 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT03899792
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03899792 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study of the Oral RET Inhibitor LOXO 292 in Pediatric Patients With Advanced RET-Altered Solid or Primary Central Nervous System Tumors
Lead sponsor
Eli Lilly and Company
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
June 13, 2019
Completion date
May 31, 2029
Enrollment
36 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

infantile fibrosarcoma, infantile myofibromatosis, medullary thyroid cancer, papillary thyroid cancer, soft tissue sarcoma